{"entity":{"id":"oncoc4","kind":"company","name":"OncoC4","aka":["OncoC4, Inc."],"tldr":"OncoC4 is a United States-based biotechnology company running 5 late-stage cancer trials of ONC-392, AI-081 and ONC-392 low in non-small-cell lung cancer, melanoma and head and neck squamous cell carcinoma.","summary":"OncoC4, based in Rockville, MD, the United States, is a biotechnology company. A clinical-stage biotechnology company developing immunotherapies (monoclonal and bispecific antibodies, antibody-drug conjugates) for cancer and Alzheimer's disease, targeting CTLA-4, PD-1/VEGF, Siglec and CD24 pathways; grew out of the founders' prior work at OncoImmune following its acquisition by Merck. On ClinicalTrials.gov it is the lead sponsor of 5 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3), testing ONC-392, AI-081, ONC-392 low, ONC-392 high and Gotistobart in non-small-cell lung cancer, melanoma, head and neck squamous cell carcinoma, renal cell carcinoma and colorectal cancer. The largest, NCT04140526 (Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumours and NSCLC), plans to enrol 733 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.oncoc4.com"},{"label":"ClinicalTrials.gov: trials led by OncoC4","url":"https://clinicaltrials.gov/search?lead=OncoC4%2C%20Inc."},{"label":"Pipeline page","url":"https://www.oncoc4.com/en/pipeline/pipeline/"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["nsclc","melanoma","head-and-neck","rcc","colorectal","sarcoma","prostate","ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":["gotistobart","ai-081"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05446298","nct04140526","nct05682443","nct06635785"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Rockville, MD","country":"US","companyType":"biotech","website":"https://www.oncoc4.com","founded":2020,"stage":"growth","investors":[],"funding":[]},"route":"/companies/oncoc4/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"},{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"},{"id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/"}],"drug":[{"id":"ai-081","kind":"drug","name":"AI-081","route":"/drugs/ai-081/"},{"id":"gotistobart","kind":"drug","name":"Gotistobart","route":"/drugs/gotistobart/"}],"trial":[{"id":"nct05446298","kind":"trial","name":"ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer","route":"/trials/nct05446298/"},{"id":"nct05682443","kind":"trial","name":"ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC","route":"/trials/nct05682443/"},{"id":"nct05671510","kind":"trial","name":"ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors","route":"/trials/nct05671510/"},{"id":"nct06635785","kind":"trial","name":"Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors","route":"/trials/nct06635785/"},{"id":"nct04140526","kind":"trial","name":"Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC","route":"/trials/nct04140526/"}]}}